Trending

Regeneron

Regeneron and Alnylam announce $1bn collaboration

Regeneron and Alnylam announce $1bn collaboration

Regeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and

X

Regeneron and Alnylam announce $1bn collaboration

https://pharmaphorum.com/news/regeneron-and-alnylam-announce-1bn-collaboration/

Praluent approved to reduce CV risk in Europe

Praluent approved to reduce CV risk in Europe

The European Commission has approved Sanofi and Regeneron’s Praluent for reducing cardiovascular risk in adults with established atherosclerotic

X

Praluent approved to reduce CV risk in Europe

https://pharmaphorum.com/news/praluent-approved-to-reduce-cv-risk-in-europe/

Sanofi/Regeneron’s Dupixent shows more promise in nasal polyps

Sanofi/Regeneron’s Dupixent shows more promise in nasal polyps

Sanofi and Regeneron’s attempts to make Dupixent into a blockbuster franchise have been boosted with more strong phase

X

Sanofi/Regeneron’s Dupixent shows more promise in nasal polyps

https://pharmaphorum.com/news/sanofi-regenerons-dupixent-shows-more-promise-in-nasal-polyps/

Sanofi gets opt-in rights to two Regeneron cancer drugs

Sanofi gets opt-in rights to two Regeneron cancer drugs

Sanofi and Regeneron have restructured and extended their immune-oncology discovery and development agreement, giving the French drugmaker rights

X

Sanofi gets opt-in rights to two Regeneron cancer drugs

https://pharmaphorum.com/news/sanofi-gets-opt-in-rights-to-two-regeneron-cancer-drugs/

Praluent not worth the price, finds study

Praluent not worth the price, finds study

Sanofi and Regeneron’s Praluent may still not be cost effective compared to other cholesterol-lowering drugs despite a recent

X

Praluent not worth the price, finds study

https://pharmaphorum.com/news/praluent-not-worth-the-price-finds-study/

Amgen cuts US price of cholesterol drug by 60%

Amgen cuts US price of cholesterol drug by 60%

Amgen is cutting the US price of its cholesterol drug Repatha by 60%, following a similar decision by

X

Amgen cuts US price of cholesterol drug by 60%

https://pharmaphorum.com/news/amgen-cuts-us-price-of-cholesterol-drug-by-60/

FDA approves Sanofi/Regeneron’s Dupixent in asthma

FDA approves Sanofi/Regeneron’s Dupixent in asthma

The US regulator has approved Sanofi/Regeneron’s Dupixent (dupilumab) in a new asthma indication, a key step in the

X

FDA approves Sanofi/Regeneron’s Dupixent in asthma

https://pharmaphorum.com/news/fda-approves-sanofi-regenerons-dupixent-in-asthma/

Sanofi/Regeneron’s Dupixent could be first biologic approved for nasal polyps

Sanofi/Regeneron’s Dupixent could be first biologic approved for nasal polyps

Trials of Sanofi and Regeneron’s drug Dupixent (dupilumab) have shown positive results for treating patients suffering from chronic

X

Sanofi/Regeneron’s Dupixent could be first biologic approved for nasal polyps

https://pharmaphorum.com/news/sanofi-regenerons-dupixent-could-be-first-biologic-approved-for-nasal-polyps/

Regeneron/Teva pain drug fasinumab on target in phase 3

Regeneron/Teva pain drug fasinumab on target in phase 3

Pfizer and Eli Lilly are competitors in NGF research

X

Regeneron/Teva pain drug fasinumab on target in phase 3

https://pharmaphorum.com/news/regeneron-teva-pain-drug-fasinumab-target-phase-3/

1 2 3 4

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com